Context Therapeutics Gets Clearance of IND for Phase 1 Clinical trial of CTIM-76

Context Therapeutics Gets Clearance of IND for Phase 1 Clinical trial of CTIM-76

By, Admin 6 May 2024

Context Therapeutics receives US FDA clearance of IND application for phase 1 clinical trial of CTIM-76

Overview

Philadelphia-headquartered Context Therapeutics Inc, a biopharmaceutical company advancing medicines for solid tumors, announced that the US FDA has cleared its Investigational New Drug application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. The company anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in mid-2024.

Words from CEO: Context

  • “The US FDA’s clearance of our IND marks an important achievement for Context, allowing us to proceed with the phase 1 clinical programme for this potentially best-in-class CLDN6-targeting therapy,” said Martin Lehr, CEO of Context. 
  • “We look forward to the expected dosing of the first patient with CTIM-76 in the coming months, and we believe the company is well-positioned to achieve key programme milestones.”
  • Phase 1 clinical trial
  • The phase 1 clinical trial is expected to be an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. 
  • The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. 
  • The study is expected to enroll up to 70 patients.

CTIM-76

  • CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. 
  • CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. 
  • Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.
  • Context’s clinical stage product candidate, CTIM-76, is a selective CLDN6 x CD3 bispecific antibody for CLDN6-positive tumours. 
  • CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!